A Reliable Research Partner in Life Science and Medicine

Recombinant Human GRK6/GPRK6 Protein (His &GST Tag)

Catalog Number: PKSH030350

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description

Species Human

Source Baculovirus-Insect Cells-derived Human GRK6/GPRK6 protein Met 1-Arg 589, with an

N-terminal His & GST

 Calculated MW
 95.1 kDa

 Observed MW
 85 kDa

 Accession
 P43250-2

Bio-activity The specific activity was determined to be 7 nmol/min/mg using casein as substrate.

Properties

Purity > 93 % as determined by reducing SDS-PAGE.

Concentration Subject to label value.

Endotoxin $< 1.0 \text{ EU per } \mu\text{g}$ of the protein as determined by the LAL method.

Storage Storage Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.


Shipping This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel

packs. Upon receipt, store it immediately at < - 20°C.

Formulation Supplied as sterile solution of 20mM Tris, 500mM NaCl, 2mM GSH, 0.5mM PMSF,

pH 7.4

Data



> 93 % as determined by reducing SDS-PAGE.

Background

Gprotein-coupled receptor kinase 6, also known as Gprotein-coupled receptor kinase GRK6, GRK6 and GPRK6, is a lipid-anchor protein which belongs to the protein kinase superfamily, AGC Ser/Thr protein kinase family and GPRK subfamily. GRK6 / GPRK6 contains one AGC-kinase C-terminal domain, one protein kinase domain and one RGS domain. This protein phosphorylates the activated forms of G protein-coupled receptors thus initiating their deactivation. Several transcript variants encoding different isoforms have been described. GRK6 / GPRK6 is widely expressed. GRK6 / GPRK6 silencing causes suppression of signal transducer and activator of transcription 3 (STAT3) phosphorylation associated with reduction in MCL1 levels and phosphorylation, illustrating a potent mechanism for the cytotoxicity of GRK6 inhibition in multiple myeloma (MM) tumor cells. GRK6 also appears to be involved in responses to morphine. Inhibition of GRK6 represents a uniquely targeted novel therapeutic strategy in human multiple myeloma.

For Research Use Only